CLINICAL WHITE PAPER

Muscular Strength as a Clinical Vital Sign

Grip Strength and Chair-Stand Performance:Interpretation Frameworks for Clinical Practice

Dr Edward Leatham Consultant Cardiologist Jan 2026

For use in clinical assessment, patient education, and longitudinal monitoring
Version 1.0 · 2025

Executive Summary

Muscular strength is no longer a metric confined to sports medicine or rehabilitation. A robust and rapidly expanding evidence base positions grip strength and lower-limb functional capacity as powerful, independent predictors of disability, frailty, cardiovascular morbidity, and all-cause mortality across the entire adult life course.

This white paper presents clinically grounded interpretation frameworks for two widely available, low-cost measures of muscular strength: absolute hand-grip strength (kg), the height-normalised grip index (NGI, kg/m²), and the 30-second chair-stand test (repetitions). These frameworks offer five-band classification systems — from Markedly Reduced to High Reserve — stratified by age and sex.

The interpretation bands presented here are original clinical constructs informed by the shape, sex differences, and age-related trajectories documented across large international normative datasets. They are not reproductions of published percentile tables. They are designed for clinical interpretation, patient education, and longitudinal tracking — not for diagnostic labelling.

1. Introduction: Strength as a Vital Sign

The measurement of muscular strength has historically been peripheral to routine clinical assessment, viewed as relevant only to physical therapists, sports physicians, or geriatricians managing established frailty. This paradigm is changing.

Grip strength, measurable in under 30 seconds with an inexpensive hand dynamometer, has emerged as one of the most prognostically informative single measurements available to the clinician. It predicts hospitalisation duration, post-operative complications, incident disability, cardiovascular events, and mortality with a consistency that rivals established biomarkers. The 30-second chair-stand test similarly encodes a wealth of functional data — lower-limb strength, power, coordination, and cardiorespiratory reserve — in a test requiring no equipment beyond a standard chair.

The case for integrating these measures into routine assessment rests on four pillars:

- Predictive validity: grip strength and chair-stand performance predict mortality, hospitalisation, and disability with effect sizes comparable to classical cardiometabolic risk markers.
- Modifiability: both decline with disuse and respond measurably to resistance training and physical activity programmes.
- Patient engagement: objective, personalised performance data motivates behaviour change in ways that population statistics rarely achieve.
- Cost-effectiveness: testing requires minimal equipment, clinician time, or patient burden.

This white paper provides clinicians with a practical framework for interpreting these measurements in the context of individual patient care. It is explicitly *not* a diagnostic tool, and the interpretation

bands presented should always be contextualised alongside clinical history, comorbidities, testing conditions, and clinician judgement.

2. Hand-Grip Strength

2.1 Clinical Rationale

Hand-grip strength measured with a calibrated hand dynamometer is the single most widely validated index of global muscular strength in research and clinical literature. Its predictive associations with health outcomes are well-established and span multiple organ systems:

- All-cause and cardiovascular mortality: in a seminal prospective cohort study of 140,000 adults across 17 countries, each 5 kg decrement in grip strength was associated with a 16% higher risk of cardiovascular death and a 17% higher risk of all-cause death, independent of physical activity and other confounders.
- Disability and functional decline: low grip strength predicts future mobility limitation, difficulty with activities of daily living, and loss of independence.
- Frailty and sarcopenia: reduced grip strength is a core criterion in both the European Working Group on Sarcopenia in Older People (EWGSOP2) definition of sarcopenia and the Fried frailty phenotype.
- Hospitalisation and surgical risk: pre-operative grip strength is among the strongest predictors of post-surgical complications, length of stay, and 30-day readmission.

2.2 Measurement Guidance

For clinical testing, a calibrated hydraulic or electronic hand dynamometer (e.g. Jamar, Saehan) should be used. The following protocol is recommended:

- Patient seated, shoulder adducted, elbow at 90°, wrist in neutral.
- Dominant hand tested first; three trials per hand with 60-second rest intervals.
- Record the maximum value achieved across all trials.
- Clinically significant differences between dominant and non-dominant hand (>10%) may indicate asymmetric pathology and warrant further evaluation.

Grip strength is influenced by pain, acute illness, hand dominance, testing position, and device calibration. Results should be interpreted in the context of these factors.

2.3 Absolute Grip Strength (kg): Interpretation Bands

The following tables classify absolute grip strength by age and sex into five functional bands. Thresholds reflect the overall shape, sex differences, and age-related decline consistently reported in large population-based normative studies, and are designed as an original clinical framework.

Interpretation Band Key

	Markedly reduced	Clinically significant weakness; warrants further assessment and targeted intervention.
	Below expected	Below age-sex norm; consider lifestyle counselling and structured exercise referral.
	Age-typical	Within expected range for age and sex; reinforcement of healthy behaviours.
	Above average	Functional reserve above the norm; associated with reduced frailty and mortality risk.
	High reserve	Optimal functional reserve; prognostically favourable; continue maintenance strategies.

Table 1a. Absolute Grip Strength — Men (kg)

Age	Markedly reduced	Below expected	Age-typical	Above average	High reserve
20–39	<28	28–34	35–41	42–50	>50
40–59	<26	26–32	33–39	40–47	>47
60–69	<24	24–29	30–36	37–44	>44
70–79	<20	20–26	27–33	34–40	>40
80+	<16	16–22	23–28	29–34	>34

Clinical interpretation bands for absolute hand-grip strength in men, by age group.

Table 1b. Absolute Grip Strength — Women (kg)

Age	Markedly reduced	Below expected	Age-typical	Above average	High reserve
20–39	<18	18–22	23–27	28–33	>33
40–59	<16	16–20	21–25	26–30	>30
60–69	<14	14–18	19–23	24–28	>28
70–79	<12	12–16	17–21	22–26	>26
80+	<10	10–14	15–18	19–22	>22

Clinical interpretation bands for absolute hand-grip strength in women, by age group.

2.4 Normalised Grip Index (NGI, kg/m²): Interpretation Bands

Absolute grip strength is influenced by body size, particularly height. Two individuals with identical grip strength but different statures may have meaningfully different muscular capability relative to their frame. The Normalised Grip Index (NGI) addresses this by expressing grip strength relative to height squared, analogous to the body mass index.

NGI (kg/m²) = Grip strength (kg) ÷ Height (m)²

For example, a grip strength of 30 kg in an individual 1.70 m tall yields an NGI of 30 ÷ 2.89 = 10.4 kg/m². This height-adjusted metric may be particularly useful when comparing patients across a wide range of statures or tracking individuals over time.

Reporting convention: *Where both absolute grip and NGI are recorded, if the two classification bands differ, the lower band (i.e. the more conservative interpretation) should be used as the primary clinical classification.*

Table 2a. Normalised Grip Index (NGI) — Men (kg/m²)

Age	Markedly reduced	Below expected	Age-typical	Above average	High reserve
20–39	<9.0	9.0–10.4	10.5–11.9	12.0–13.4	≥13.5
40–59	<8.6	8.6–9.9	10.0–11.3	11.4–12.7	≥12.8
60–69	<8.0	8.0–9.2	9.3–10.6	10.7–12.0	≥12.1
70–79	<7.2	7.2–8.4	8.5–9.7	9.8–11.0	≥11.1
80+	<6.3	6.3–7.4	7.5–8.6	8.7–9.8	>9.9

Clinical interpretation bands for height-normalised grip strength (NGI) in men, by age group.

Table 2b. Normalised Grip Index (NGI) — Women (kg/m²)

Age	Markedly reduced	Below expected	Age-typical	Above average	High reserve
20–39	<6.1	6.1–7.0	7.1–8.0	8.1–9.0	≥9.1
40–59	<5.7	5.7–6.6	6.7–7.6	7.7–8.6	≥8.7
60–69	<5.2	5.2–6.0	6.1–6.9	7.0–7.8	≥7.9
70–79	<4.7	4.7–5.4	5.5–6.2	6.3–7.0	≥7.1
80+	<4.1	4.1–4.8	4.9–5.6	5.7–6.4	≥6.5

Clinical interpretation bands for height-normalised grip strength (NGI) in women, by age group.

3. The 30-Second Chair-Stand Test

3.1 Clinical Rationale

The 30-second chair-stand test is a practical, equipment-free functional measure that quantifies lower-limb strength, power, balance, and endurance in a single timed trial. It is widely used in geriatric medicine, sports science, and chronic disease management, with strong associations with:

- Falls risk and mobility limitation in older adults.
- Frailty and sarcopenia status, with performance thresholds embedded in multiple validated screening tools.
- Cardiometabolic risk: lower chair-stand performance is independently associated with adverse cardiovascular outcomes and metabolic syndrome components.
- Functional independence and quality of life in both healthy older adults and those with chronic conditions.

Unlike grip strength, chair-stand performance is not routinely normalised for height or body weight in clinical practice. Repetition count captures functional capacity in a manner directly meaningful to daily activities such as rising from a chair, stair climbing, and transfer manoeuvres.

3.2 Measurement Protocol

The standardised 30-second chair-stand test protocol is as follows:

- Use a straight-backed chair of standard height (approximately 43–45 cm seat height), placed against a wall for safety.
- Patient begins seated, arms folded across the chest, feet flat on the floor.
- On the command 'Go', the patient stands fully upright and returns to a fully seated position as many times as possible in 30 seconds.
- A repetition is counted each time the patient achieves full hip extension in the standing position.
- If a patient is more than halfway to standing at the 30-second mark, that repetition is counted.

Patients should be warned not to use their hands unless safety requires it. The test is contraindicated in those with acute lower-limb injury or instability, and should be supervised in those with significant balance impairment or significant cardiovascular disease.

3.3 Interpretation Bands

The following interpretation bands apply to adults aged 60 years and older, reflecting the population in whom chair-stand testing has the greatest clinical utility and for whom normative data are most robust. The bands are intentionally conservative at the lower threshold to flag individuals who may benefit from further frailty, sarcopenia, or mobility assessment.

Table 3a. 30-Second Chair-Stand Test — Men (repetitions)

Age	Markedly reduced	Below expected	Age-typical	Above average	High reserve
60–69	≤8	9–11	12–14	15–17	≥18
70–79	≤7	8–10	11–13	14–16	≥17
80+	≤6	7–9	10–12	13–15	≥16

Clinical interpretation bands for 30-second chair-stand performance in men aged 60 and over.

Table 3b. 30-Second Chair-Stand Test — Women (repetitions)

Age	Markedly reduced	Below expected	Age-typical	Above average	High reserve
60–69	≤9	10–12	13–15	16–18	≥19
70–79	≤8	9–11	12–14	15–17	≥18
80+	≤7	8–10	11–13	14–16	≥17

Clinical interpretation bands for 30-second chair-stand performance in women aged 60 and over.

4. Clinical Application

4.1 Screening and Risk Stratification

Both grip strength and the chair-stand test are most useful when integrated into a structured clinical assessment pathway. Suggested trigger points for assessment include:

- Annual health check or preventive medicine review in adults aged ≥40 years.
- Pre-operative assessment for major elective surgery.
- Chronic disease reviews (cardiovascular disease, type 2 diabetes, chronic kidney disease, COPD, cancer survivorship).
- Any presentation with unintentional weight loss, fatigue, or reduced exercise tolerance.
- Geriatric assessment, falls review, or frailty screening.

A finding in the Markedly Reduced band should prompt consideration of further frailty and sarcopenia evaluation, nutritional assessment, and onward referral to physiotherapy or exercise medicine as appropriate. A finding in the Below Expected band warrants structured counselling on resistance exercise and lifestyle physical activity.

4.2 Longitudinal Monitoring

Serial measurement is arguably more informative than any single cross-sectional value. Tracking strength over time allows:

- Early detection of accelerated decline, which may signal occult illness or nutritional insufficiency before clinical symptoms emerge.
- Objective assessment of the response to structured exercise programmes, rehabilitation, or nutritional interventions.
- Motivational feedback for patients: visible progress on an objective functional metric is a powerful behaviour change tool.

A decline of ≥5 kg in grip strength or ≥2 repetitions in chair-stand performance over 12 months should be considered clinically significant and prompt reassessment.

4.3 Contextual Interpretation

These interpretation bands are population-derived constructs and should be applied with clinical judgement. Factors that may modify interpretation include:

- Testing conditions and technique: standardised protocols are essential for between-visit comparability.
- Hand dominance: dominant hand typically generates 5–10% greater grip force; document which hand is tested.
- Musculoskeletal pain, acute illness, or recent surgery may transiently depress grip strength independently of underlying functional status.
- Chair height: variations from the standard 43–45 cm seat height will affect chair-stand performance.
- Body composition: in individuals with extreme body mass index values, absolute grip strength may better reflect function than the NGI and vice versa.

5. Methods Note: Construction of Interpretation Bands

The interpretation bands presented in this white paper are original clinical constructs. They were developed through the following process:

- Age bands were defined in clinically intuitive groupings that reflect recognised life-course changes in muscular strength.
- Threshold values were calibrated to approximate broad population strata (low, typical, high functional reserve) as reported in large-scale international normative studies, preserving known sex differences and age-related trajectories.
- Internal consistency was verified across age groups to ensure plausible transitions with ageing, avoiding artificially sharp or implausible step changes between adjacent bands.
- No single published normative table, figure, or dataset was reproduced, encoded, or directly adapted. The supporting literature informed the conceptual framework and the shape of the normative distribution only.

These bands are intended for clinical education and longitudinal patient monitoring. They should not be used for formal diagnostic classification of sarcopenia or frailty, which requires application of validated diagnostic criteria (e.g. EWGSOP2 for sarcopenia, Fried criteria for frailty) and, where appropriate, additional measures such as muscle mass quantification.

6. Implications for Intervention

Grip strength and chair-stand performance are modifiable. The evidence supporting resistance and functional exercise training as the primary intervention for low muscular strength is extensive and consistent. Key evidence-based principles for clinical recommendation include:

- Progressive resistance training (PRT): two to three sessions per week, targeting major muscle groups, with progressive overload, is the most effective intervention for improving both grip strength and lower-limb functional capacity in older adults.
- Protein adequacy: dietary protein intake of 1.2–1.6 g/kg body weight per day is recommended in older adults at risk of sarcopenia, distributed across meals to optimise muscle protein synthesis.
- Aerobic conditioning: combined aerobic and resistance exercise programmes produce greater functional gains than either modality alone.
- Fall prevention programmes: structured multicomponent exercise programmes (balance, strength, and functional training) reduce falls in community-dwelling older adults and improve chair-stand performance.

Clinicians should refer patients with Markedly Reduced strength to physiotherapy or an accredited exercise physiologist for supervised, individualised programming. Those in the Below Expected band should receive structured advice and, where resources permit, supervised group or individual exercise referral.

7. Supporting Literature

1. Tomkinson GR, Lang JJ, Rubín L, et al. International norms for adult handgrip strength: a systematic review of data on 2.4 million adults aged 20 to 100+ years from 69 countries and regions. *J Sport Health Sci.* 2025;14:101014. doi:10.1016/j.jshs.2024.101014. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC11863340/

2. Bohannon RW. Hand-grip dynamometry predicts future outcomes in aging adults. *J Geriatr Phys Ther.* 2008;31(1):3–10. doi:10.1519/00139143-200831010-00002. URL: https://pubmed.ncbi.nlm.nih.gov/18489802/

3. Cooper R, Kuh D, Hardy R. Objectively measured physical capability levels and mortality: systematic review and meta-analysis. *BMJ.* 2010;341:c4467. doi:10.1136/bmj.c4467. URL: https://www.bmj.com/content/341/bmj.c4467

4. Dodds RM, Syddall HE, Cooper R, et al. Grip strength across the life course: normative data from twelve British studies. *PLoS One.* 2014;9(12):e113637. doi:10.1371/journal.pone.0113637. URL: https://journals.plos.org/plosone/article?id=10.1371/journal.pone.0113637

5. Cruz-Jentoft AJ, Bahat G, Bauer J, et al. Sarcopenia: revised European consensus on definition and diagnosis (EWGSOP2). *Age Ageing.* 2019;48(1):16–31. doi:10.1093/ageing/afy169. URL: https://academic.oup.com/ageing/article/48/1/16/5126243

6. Leong DP, Teo KK, Rangarajan S, et al. Prognostic value of grip strength: findings from the Prospective Urban Rural Epidemiology (PURE) study. *Lancet.* 2015;386(9990):266–273. doi:10.1016/S0140-6736(14)62000-6. URL: https://pubmed.ncbi.nlm.nih.gov/25982160/

7. Alcazar J, Losa-Reyna J, Rodriguez-Lopez C, Alfaro-Acha A, Rodriguez-Mañas L, Ara I, García-García FJ, Alegre LM. The sit-to-stand muscle power test: an easy, inexpensive and portable procedure to assess muscle power in older people. *Exp Gerontol.* 2018;112:38–43. doi:10.1016/j.exger.2018.08.006. URL: https://pubmed.ncbi.nlm.nih.gov/30096459/

8. Alcazar J, Kamper RS, Aagaard P, Haddock B, Prescott E, Ara I, Suetta C. Relation between leg extension power and 30-s sit-to-stand muscle power in older adults: validation and translation to functional performance. *Sci Rep.* 2020;10(1):16337. doi:10.1038/s41598-020-73395-4. URL: https://www.nature.com/articles/s41598-020-73395-4

9. Alcazar J, Alegre LM, Van Roie E, Magalhães JP, Nielsen BR, González-Gross M, et al. Relative sit-to-stand power: aging trajectories, functionally relevant cut-off points, and normative data in a large European cohort. *J Cachexia Sarcopenia Muscle.* 2021;12(4):921–932. doi:10.1002/jcsm.12737. URL: https://onlinelibrary.wiley.com/doi/10.1002/jcsm.12737

10. Alcazar J, Aagaard P, Haddock B, Kamper RS, Hansen SK, Prescott E, et al. Assessment of functional sit-to-stand muscle power: cross-sectional trajectories across the lifespan. *Exp Gerontol.* 2021;152:111448. doi:10.1016/j.exger.2021.111448. URL: https://pubmed.ncbi.nlm.nih.gov/34118363/

11. Gill S, Hely R, Page RS, Hely A, Harrison B, Landers S. Thirty-second chair stand test: test-retest reliability, agreement and minimum detectable change in people with early-stage knee osteoarthritis. *Physiother Res Int.* 2022;27(3):e1957. doi:10.1002/pri.1957. URL: https://pubmed.ncbi.nlm.nih.gov/35491422/

12. Kuo YL. The influence of chair seat height on the performance of community-dwelling older adults' 30-second chair stand test. *Aging Clin Exp Res.* 2013;25(3):305–309. doi:10.1007/s40520-013-0041-x. URL: https://pubmed.ncbi.nlm.nih.gov/23949884/

13. Sawada S, Ozaki H, Natsume T, Deng P, Yoshihara T, Nakagata T, et al. The 30-s chair stand test as a screening tool for sarcopenia in elderly Japanese participants. *BMC Musculoskelet Disord.* 2021;22(1):639. doi:10.1186/s12891-021-04524-x. URL: https://bmcmusculoskeletdisord.biomedcentral.com/articles/10.1186/s12891-021-04524-x

14. Wright AA, Cook CE, Baxter GD, Dockerty JD, Abbott JH. A comparison of three methodological approaches to defining major clinically important improvement of four performance measures in patients with hip osteoarthritis. *J Orthop Sports Phys Ther.* 2011;41(5):319–327. doi:10.2519/jospt.2011.3515. URL: https://pubmed.ncbi.nlm.nih.gov/21335930/

15. Campitelli A, Paulson S, Vincenzo J, Glenn JM, Gills JL, Jones MD, Powers M, Gray M. Sit-to-stand power across the lifespan: a cross-sectional analysis. *J Aging Phys Act.* 2022;30(4):678–688. doi:10.1123/japa.2021-0066. URL: https://pmc.ncbi.nlm.nih.gov/articles/PMC10209912/

16. Tolk JJ, Janssen RPA, Prinsen CAC, Latijnhouwers DAJM, van der Steen MC, Bierma-Zeinstra SMA, Reijman M. The OARSI core set of performance-based measures for knee osteoarthritis is reliable but not valid and responsive. *Knee Surg Sports Traumatol Arthrosc.* 2019;27(9):2898–2909. doi:10.1007/s00167-017-4789-y. URL: https://link.springer.com/article/10.1007/s00167-017-4789-y

17. Physiotutors. What can we learn from the 30-second chair stand test? URL: https://www.physiotutors.com/30s-chair-stand-test/

IMPORTANT NOTICE

This white paper is intended for healthcare professionals as an educational resource. The interpretation bands presented are original clinical frameworks designed to support clinical discussion, patient education, and longitudinal monitoring. They are not diagnostic instruments and do not replace validated diagnostic criteria for sarcopenia, frailty, or any other clinical condition. All results must be interpreted in the context of full clinical assessment, individual patient history, and professional judgement. This document does not constitute medical advice.